menu search

MNPR / Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data

Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data
Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tissue sarcoma. Read More
Posted: Nov 18 2022, 15:11
Author Name: Zacks Investment Research
Views: 102510

MNPR News  

Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

By Zacks Investment Research
May 29, 2023

Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics Inc. (MNPR), indicating that the stock has found suppo more_horizontal

Why Is Monopar Therapeutics (MNPR) Stock Down 47% Today?

By InvestorPlace
March 28, 2023

Why Is Monopar Therapeutics (MNPR) Stock Down 47% Today?

Monopar Therapeutics (NASDAQ: MNPR ) stock is taking a beating on Tuesday after the company revealed lackluster clinical trial results. These results more_horizontal

Monopar to Present at the Jefferies Radiopharma Innovation Summit

By GlobeNewsWire
March 28, 2023

Monopar to Present at the Jefferies Radiopharma Innovation Summit

WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on dev more_horizontal

Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data

By Zacks Investment Research
November 18, 2022

Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data

Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tis more_horizontal


Search within

Pages Search Results: